Literature DB >> 19966626

Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota.

Stefan D Holubar1, Kirsten Hall Long, Edward V Loftus, Bruce G Wolff, John H Pemberton, Robert R Cima.   

Abstract

PURPOSE: This study was designed to test the hypothesis that patients undergoing definitive surgery for chronic ulcerative colitis have reduced direct medical costs after, as compared with before, total proctocolectomy.
METHODS: A population-based cohort of patients who underwent proctocolectomy for ulcerative colitis from 1988 to 2007 was identified using the Rochester Epidemiology Project. Total direct healthcare costs were estimated from an administrative database. The primary outcome was the observed cost difference between the two-year period before surgery and the two-year period after a surgery/recovery period (surgery + 180 days). Statistical significance was assessed using paired t-tests and bootstrapping methods. Demographic data were presented as median (interquartile range) or frequency (proportion). Mean costs are reported in 2007 constant dollars.
RESULTS: Sixty patients were Olmsted County, Minnesota, residents at the time of surgery and for the entire period of observation. Overall 40 patients (66%) were men, median age was 42 (range, 31-52) years, and duration of median colitis was four (range, 1-11) years. Operations included ileal pouch-anal anastomosis (n = 45, mean cost of surgery/recovery period = $50,530) and total proctocolectomy with Brooke ileostomy (n = 15, mean cost of surgery/recovery period = $39,309). In the pouch subgroup, direct medical costs on average were reduced by $9,296 (P < 0.001, bootstrapped 95% confidence interval: $324-$15,628) during the two years after recovery. In the Brooke ileostomy subgroup, direct medical costs on average were reduced by $12,529 (P < 0.001, bootstrapped 95% confidence interval: $6,467-$18,688) in the two years after recovery.
CONCLUSION: Surgery for chronic ulcerative colitis resulted in reduced direct costs in the two years after surgical recovery. These observations suggest that surgical intervention for ulcerative colitis is associated with long-term economic benefit.

Entities:  

Mesh:

Year:  2009        PMID: 19966626      PMCID: PMC2791910          DOI: 10.1007/DCR.0b013e3181b327a6

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  41 in total

1.  Risk factors for ileoanal J pouch-related septic complications in ulcerative colitis and familial adenomatous polyposis.

Authors:  Udo A Heuschen; Ulf Hinz; Erik H Allemeyer; Frank Autschbach; Josef Stern; Matthias Lucas; Christian Herfarth; Gundi Heuschen
Journal:  Ann Surg       Date:  2002-02       Impact factor: 12.969

Review 2.  Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.

Authors:  A H Briggs; D E Wonderling; C Z Mooney
Journal:  Health Econ       Date:  1997 Jul-Aug       Impact factor: 3.046

3.  Predicting the cost of illness: a comparison of alternative models applied to stroke.

Authors:  J Lipscomb; M Ancukiewicz; G Parmigiani; V Hasselblad; G Samsa; D B Matchar
Journal:  Med Decis Making       Date:  1998 Apr-Jun       Impact factor: 2.583

4.  Surgery for ulcerative colitis.

Authors:  J H Pemberton
Journal:  Surg Clin North Am       Date:  1987-06       Impact factor: 2.741

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

6.  Morbidity of medical therapy for ulcerative colitis: what are we really saving?

Authors:  M E Sher; E G Weiss; J J Nogueras; S D Wexner
Journal:  Int J Colorectal Dis       Date:  1996       Impact factor: 2.571

7.  Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.

Authors:  Michael D Kappelman; Sheryl L Rifas-Shiman; Carol Q Porter; Daniel A Ollendorf; Robert S Sandler; Joseph A Galanko; Jonathan A Finkelstein
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

8.  Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis.

Authors:  Chelliah R Selvasekar; Robert R Cima; David W Larson; Eric J Dozois; Jeffrey R Harrington; William S Harmsen; Edward V Loftus; William J Sandborn; Bruce G Wolff; John H Pemberton
Journal:  J Am Coll Surg       Date:  2007-05       Impact factor: 6.113

9.  Sexual function, body image, and quality of life after laparoscopic and open ileal pouch-anal anastomosis.

Authors:  David W Larson; Michael M Davies; Eric J Dozois; Robert R Cima; Karen Piotrowicz; Kari Anderson; Sunni A Barnes; W Scott Harmsen; Tonia M Young-Fadok; Bruce G Wolff; John H Pemberton
Journal:  Dis Colon Rectum       Date:  2008-01-24       Impact factor: 4.585

10.  Minimally invasive total proctocolectomy with Brooke ileostomy for ulcerative colitis.

Authors:  Stefan D Holubar; Antonio Privitera; Robert R Cima; Eric J Dozois; John H Pemberton; David W Larson
Journal:  Inflamm Bowel Dis       Date:  2009-09       Impact factor: 5.325

View more
  6 in total

1.  Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.

Authors:  Sameer D Saini; Akbar K Waljee; Peter D R Higgins
Journal:  Clin Gastroenterol Hepatol       Date:  2012-05-18       Impact factor: 11.382

2.  Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis.

Authors:  Gauree Gupta Konijeti; Mark G Shrime; Ashwin N Ananthakrishnan; Andrew T Chan
Journal:  Gastrointest Endosc       Date:  2013-11-18       Impact factor: 9.427

3.  Stool DNA Analysis is Cost-Effective for Colorectal Cancer Surveillance in Patients With Ulcerative Colitis.

Authors:  John B Kisiel; Gauree G Konijeti; Andrew J Piscitello; Tarun Chandra; Thomas F Goss; David A Ahlquist; Francis A Farraye; Ashwin N Ananthakrishnan
Journal:  Clin Gastroenterol Hepatol       Date:  2016-07-25       Impact factor: 11.382

4.  Drivers of cost after surgical and medical therapy for chronic ulcerative colitis: a nested case-cohort study in Olmsted County, Minnesota.

Authors:  Stefan D Holubar; Rajesh Pendlimari; Edward V Loftus; James P Moriarty; Dirk Larson; Megan O'Byrne; John H Pemberton; Robert R Cima
Journal:  Dis Colon Rectum       Date:  2012-12       Impact factor: 4.585

5.  Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis.

Authors:  Candace L Beilman; Nguyen Xuan Thanh; Victoria Ung; Christopher Ma; Karen Wong; Karen I Kroeker; Thomas Lee; Haili Wang; Arto Ohinmaa; Phil Jacobs; Brendan P Halloran; Richard N Fedorak
Journal:  Can J Gastroenterol Hepatol       Date:  2016-10-03

6.  Short-term outcomes and healthcare resource utilization following incisional hernia repair with synthetic mesh in patients with Crohn's disease.

Authors:  B C Perlmutter; H Alkhatib; A L Lightner; A Fafaj; S J Zolin; C C Petro; D M Krpata; A S Prabhu; S D Holubar; M J Rosen
Journal:  Hernia       Date:  2021-08-03       Impact factor: 4.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.